CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Heather L. Franklin Joins XOMA's Board of Directors

Life Sciences Review Life Sciences Review | Wednesday, August 18, 2021
Tweet

Heather L. Franklin will expand XOMA’s portfolio of potential royalty assets via acquisition transactions.


FREMONT, CA: XOMA Corporation announces that Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the company’s Board of Directors. Ms. Franklin has notable experience in corporate development and strategy, including over ten years of experience founding and leading Blaze and ten years of business development experience before that at ZymoGenetics.


“We warmly welcome Heather to the XOMA Board of Directors. Heather is a highly regarded C-level executive leading Blaze, a development-stage oncology company. Heather has structured and negotiated deals across the product development spectrum from research through commercialization. Her background in business development and program management will benefit the XOMA team as we execute on our royalty aggregator business model and continue to grow our royalty portfolio,” said Jim Neal, Chief Executive Officer at XOMA.


“I am excited to join XOMA with its clear focus on expanding its portfolio of potential royalty assets via acquisition transactions. The XOMA strategy fits nicely with my licensing and transactions background and experience.


 I look forward to joining the Board and helping the CompanyCompany provide an innovative financing alternative for early to mid-clinical stage biotechnology companies,” commented Ms. Franklin.


Ms. Franklin has over 20 years of broad biotechnology expertise. She established Blaze Bioscience in 2011 and has led the company from its infancy to become a clinical-stage company. Before establishing Blaze, Ms. Franklin spent ten years at ZymoGenetics in positions of increasing responsibility, ultimately serving as senior vice president, business development, where she was a member of the executive management team and was held for business development, alliance management, strategic planning, portfolio management, and pipeline marketing. Ms. Franklin was the architect of the $1.1 billion deal with Bristol Myers Squibb for interferon lambda, which was the largest single-molecule Phase 1 deal ever consummated and eventually led to the subsequent acquisition of BMS. Earlier in her career, she held roles in program management at Amgen and Targeted Genetics. Ms. Franklin has a Master’s degree in Business and Administration from The Warton School of the University of Pennsylvania, her Masters of Science from the University of Washington, and her bachelor of science from the University of North Carolina at Chapel Hill.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/heather-l-franklin-joins-xoma-s-board-of-directors-nwid-507.html